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Abstract
Background: There is general agreement amongst biologists about the need for good pathway diagrams and a need 
to formalize the way biological pathways are depicted. However, implementing and agreeing how best to do this is 
currently the subject of some debate.
Results: The modified Edinburgh Pathway Notation (mEPN) scheme is founded on a notation system originally 
devised a number of years ago and through use has now been refined extensively. This process has been primarily 
driven by the author's attempts to produce process diagrams for a diverse range of biological pathways, particularly 
with respect to immune signaling in mammals. Here we provide a specification of the mEPN notation, its symbols, rules 
for its use and a comparison to the proposed Systems Biology Graphical Notation (SBGN) scheme.
Conclusions: We hope this work will contribute to the on-going community effort to develop a standard for depicting 
pathways and will provide a coherent guide to those planning to construct pathway diagrams of their biological 
systems of interest.
Background
Pathway diagrams are currently available in a plethora of
different forms. Using the term in the broadest sense,
they can be a picture that accompanies a review article,
wall charts distributed by journals and companies, small
schematic diagrams used to support mathematical mod-
eling efforts or network graphs reflecting known protein
interactions based on the results of large scale interaction
studies or automated literature mining. To support these
efforts there are also a growing number of databases that
serve up these 'pathways' [1]. These are either curated
centrally [2-5] or increasingly by the community [6-8].
The sheer range of resources available reflects the current
interest in pathway science. However, this variety can in
itself be frustrating. Pathways are drawn using informal
and idiosyncratic notation systems, with varying degrees
of accuracy and specificity in defining what pathway
components are being depicted and the relationships
between them. Resources are often fragmented with
some proteins or metabolites being members of numer-
ous pathways; the concept of pathway membership being
a highly subjective division. The pathways themselves are
rarely available as a cohesive network and there are
numerous pathway exchange formats in use. All in all,
despite the huge efforts in time and resources that has
been poured into pathway science the state of the art
leaves a lot to be desired. The advent of analytical tech-
niques able to perform genome-wide analysis of cell sys-
tems has opened a window to our comprehension of
systems-level biology. It has however also highlighted the
pressing need for comprehensive pathway models in
order to assist with the interpretation of this data.
In recognition of these issues a number of groups have
proposed formalized notation schemes for drawing 'wir-
ing diagrams' of cellular pathways [9-12]. The process
diagram notation (PDN) on which our work has been
largely based [9], has been used in the generation of a
number of relatively large pathway diagrams [13-15].
However, in the course of our investigations we have
found that the diagrams resulting from these elegant and
pioneering efforts were not always easy to interpret and
the notation system was a challenge to implement. Fur-
thermore, we found that the PDN did not support all of
the concepts that are required to reflect the diversity of
pathway components and the relationships between
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Page 2 of 13them. The original Edinburgh Pathway Notation (EPN)
scheme [11] was designed to allow the logical depiction
of signaling pathways. The basic objectives of the EPN
were to create a notation scheme that was: a) flexible
enough to allow the detailed representation of a diverse
range of biological entities, interactions and pathway con-
cepts; b) able to represent pathway knowledge in a
semantically and visually unambiguous manner; c) able to
the construct pathway diagrams that are understandable
by a biologist; and d) able to produce diagrams that are
sufficiently well defined that software tools can convert
graphical models into formal models suitable for analysis
and simulation. It incorporated many of the ideas of the
process PDN scheme but notably introduced the idea of
using Boolean logic operators (AND/OR/NOT) nodes to
represent co-dependencies between components. As our
pathway mapping efforts have continued to develop and
been driven by our interest in modeling a diverse range of
biological pathways and concepts, we found it necessary
to further refine the EPN scheme. We are now satisfied
that this graphical language has reached a sufficient level
of maturity to now formally describe the 'modified' EPN
scheme. In doing so we seek to provide a cohesive guide
for those wanting to construct any range of pathways
using the mEPN, and support our own work in depicting
the regulation of macrophage biology [16-18]. We also
believe that the mEPN scheme has some important
advantages over other proposed pathway notation
schemes and is therefore a positive contribution to the
debate on standardizing pathway depiction.
Results
Definition of the modified Edinburgh Pathway Notation 
(mEPN) Scheme
A pathway may be considered to be a directional network
of molecular interactions between components of a bio-
logical system that act together to regulate a cellular
event or process. In this context a component is any phys-
ical entity involved in a pathway e.g. a protein, protein
complex, nucleic acid (DNA, RNA), molecule, etc. Inter-
actions are generally the relationships between one com-
ponent and another where one component influences the
activity of another e.g. through its binding to, inhibition
of, catalytic conversion of, etc. Interactions between cel-
lular components thereby lead to a change in the status of
the system. A pathway notation scheme is a collection of
predefined symbols (shapes, lines, figures) that represent
the constituent parts of a graphical system for depicting
the components of a biological pathway, the interactions
between them and the cellular compartments in which
they occur. A scheme should also include rules for the use
of these symbols in depicting information. Glyphs are
stylized graphical symbols that impart information non-
verbally and are used to portray different classes of bio-
logical entities e.g. protein, gene, pathogen etc. and the
nature of the relationships between them. In network ter-
minology all glyphs are nodes (vertices) of a specific type
and the connectivity between them is defined by edges
(lines/arcs). The full set of glyphs employed in the mEPN
scheme are shown in figure 1 and a full description of
them and their use is given in the accompanying mEPN
specification document (Additional files 1 and 2).
Pathway Components
The mEPN uses a set of standard shapes to represent
classes of molecules (components) from a rounded rect-
angle to represent proteins and protein complexes, to a
diamond shaped glyph to represent simple ions and mol-
ecules e.g. Na+, K+, H2O etc. Components play some role
within the pathway and exist in one or a number of loca-
tions within a cell. An important rule of the mEPN is that
a component may only be represented once in any given
cellular compartment. Whilst this rule can potentially
lead to a tangle of edges due to certain components pos-
sessing numerous connections to other components
spread across the pathway, the benefits of the rule out-
weigh the issues in adhering to it. The number of edges
entering or leaving each node gives the reader an exact
indication of a component's connections to other compo-
nents and hence potential activity, without the need for
scanning the entire diagram to find other instances where
the component is described. A notable exception to this
rule is in the depiction of small and ubiquitously present
ions and molecules which may be represented numerous
times and be involved in numerous processes. A compo-
nent may however be shown more than once in a given
cellular compartment if it changes from one state to
another e.g. from an inactive form to an active form, in
which case both forms are represented as separate com-
ponents.
It is worth considering the depiction of protein com-
plexes as a special case. For relatively simple protein com-
plexes e.g. dimers, trimers, it is usually sufficient to depict
the complex as a simple rounded rectangle labelled using
the names of the constituent proteins and their modifica-
tions (Figure 2a). However as the size of complexes grows
this can become limiting. In the first instance a complex
may span more than one cellular compartment e.g. a
membrane receptor complex and it is useful to depict this
and the relative position of molecules within the com-
plex. In such cases we have found it useful to draw the
complex as an elongated rounded rectangle with the
names of the proteins arranged relative to their position
within the complex/cell (Figure 2b). This also has the
added advantage of reducing the reducing space a com-
plex takes up, a distinct benefit when depicting a large
number of receptors and their transient activation states.
In other cases a protein complex may have a well recogn-
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structure in its depiction. For example when depicting
various forms of the proteasome we arranged the subunit
names in layers reflecting the composition of the protea-
some's core barrel structure and placed the cap-proteins
at either end of this barrel. Whilst far from perfect it goes
some way in capturing the recognised structure of the
complex. However at a point this too becomes limiting
and when components are complexes of complexes or
complexes composed of proteins and say DNA, it is no
longer sufficient to simply represent everything as single
unified component. In such cases we have found it useful
to depict complexes as a collection of components joined
using non-directional edges (an edge without an arrow-
head) which represent a physical covalent of non-cova-
lent bond. In this way a functional entity can be seen to be
composed of multiple separate entities each of which can
be separately modified but still influence the activity and
composition as a whole (Figure 2c).
Component annotation
Multiple names are often available to describe any given
protein with a number of different protein names fre-
quently in use in the literature at any one time. Likewise
some common names may be used to describe more than
one protein or complex. This use of non-standard
nomenclature frequently leads to ambiguity as to the
exact identity of the component being depicted. Under
mEPN we therefore recommend the use of standard gene
nomenclature systems e.g. HGNC or MGD to name
human or mouse genes/proteins, respectively. These
nomenclature systems now provide a near complete
annotation of all human and mouse genes and their use in
the naming of proteins provides a direct visual link
between the identity of the gene and the corresponding
protein. Where other names (alias') are in common use
these names may be shown as an addition to the label on
the glyph representing the protein and are included as
part of the node's label after the official gene symbol in
rounded () brackets. Use of standard nomenclature also
Figure 1 List of the Glyphs used by the modified Edinburgh Pathway Notation (mEPN) scheme. Unique shapes and identifiers are used to dis-
tinguish between each element of the notation scheme. The notation scheme essentially consists of the following categories of nodes representing; 
cellular components, compartments, Boolean logic, edge annotations, reactions and processes. For a full description of the notation scheme and rules 
for its use see Additional files 1 and 2.
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data (which is usually annotated using standard nomen-
clature) with pathway models. At the present time there
are unfortunately no standard and universally recognized
nomenclature systems available for naming certain types
of pathway components. For instance protein isoforms
tend to be named in an ad hoc manner by those who
study them and biochemical compounds are known by
both their common names or by names that reflect their
chemical composition. For instance the IUPAC nomen-
clature system http://www.chem.qmul.ac.uk/iupac/ is a
standard nomenclature system for organic chemicals but
most names would have little relevance to a biologist. In
cases such as these the important thing is to be consistent
and where possible to cross reference the components ID
to other sources such that the identity of the component
depicted, where at all possible, is unambiguous.
Protein complexes when drawn as a single entity are
named as a concatenation of the proteins belonging to the
complex separated by a colon. Again if the complex is
commonly referred to by a generic name this may be
shown below the constituent parts. There are no strict
rules as to the order in which the protein names are
shown in the complex and are often shown in the order in
which proteins join the complex, in the position they are
likely to hold relative to other members of the complex
(where known) or position relative to cellular compart-
ments e.g. with receptor proteins in a membrane bound
protein complex protruding into the extra-cellular space.
Where a specific protein is present multiple times within
a complex, this may be represented by placing the num-
ber of times a protein is present within the complex in
angle brackets < >. If the number of proteins in the com-
plex is unknown this may be represented by <n>. The
Figure 2 Graphical Representation of Complexes. (A) Two alternate views of the STAT1 homodimer both of which would be considered to be 
formally correct under the mEPN scheme. (B) Visual representation of interferon-gamma receptor complex bound to IFNG. For membrane receptor 
complexes such this we have generally favoured showing the complexes spanning the plasma membrane (brown) with the receptor portion pro-
truding into the extra-cellular space (grey) and with the adaptor molecules projecting into the cytoplasm (yellow). (C) The 26S proteasome has a bar-
rel-like structure made up of 6 six concentric rings each composed of 7 proteasome subunits, capped with regulatory subunits at either end. We 
therefore chose to arrange the subunit in names in this manner so as to capture visually something of this arrangement. (D) Model of the transcription 
factor/coactivator complex that regulate genes associated with MHC class2 antigen presentation such as CD74. In this case transcription is thought 
to be regulated by two transcription factor complexes, CREB1 and one unknown factor which bind directly to four elements in the gene's promoter 
and transcription is initiated by a conformation change induced by the binding of CIITA. Here as in E interaction edges are used to denote a physical 
link between components of the complex. (E) DNA replication complex formed during S-phase. As complexes become large the use of the physical 
interaction edge becomes essential in defining not only which components make up the complex but where in the complex they reside. This arrange-
ment also allows for the depiction of specific components of the complex to undergo a change in state or cause a change in another component 
(which may or may not be part of the same complex).
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within a complex may be altered as a consequence of a
particular process. This change in the component's state
is marked using square [] brackets following the compo-
nent's name; each modification being placed in separate
brackets. This notation may be used to describe the
whole range of protein modifications from phosphoryla-
tion [P], truncation [t], ubquitinisation [Ub] etc. Where
details of the site of modification are known this may be
represented e.g. [P-L232] = phosphorylation at leucine
232. Alternatively the details of a particular modification
may be placed as a note on the node visible only during
'mouse-over' or when viewing a node's properties. Where
multiple sites are modified this may be shown using mul-
tiple brackets, each modification (state) being shown in
separate brackets.
Depiction of Interactions between Components
Interactions are depicted by edges and signify the rela-
tionships between one component and another. Edges
denote that an interaction occurs between components/
processes in a pathway and convey the directionality of
that interaction, where appropriate. The nature of an
interaction is inferred through the use of edge annotation
nodes, process nodes, and Boolean logic operators (see
below). Interaction edges may be coloured for visual
emphasis but as with nodes, the definition of meaning is
not reliant on colour. A number of edges contain an in-
line annotation node to indicate the 'type' of interaction,
as is often depicted by the use of different arrowheads.
An edge annotation is generally characterized as having
only one input and one output, and functions to describe
the type of activity implied by the edge e.g. activation,
inhibition, catalysis. However, in certain instances they
can be used as distribution nodes e.g. where one compo-
nent activates many others such as with transcriptional
activation of a number of genes by a transcription factor
it can reduce the number of edges emanating from the
transcription factor and therefore simply the representa-
tion. One other type of edge, one that connects compo-
nents but has no arrowhead, is used to depict a physical
interaction between the components. This can be used in
the depiction of a bond between separate components of
a complex, thereby providing improved visual clarity,
especially with very large complexes, as to which compo-
nents directly interact with each other.
Depiction of Biological Processes
A process is a defined event occurring between compo-
nents or to a component. A process node in the context of
this notation system can be defined as a node that infers
an action, transformation, transition or process. They
impart information on the type of process that is associ-
ated with transformation of a component from one state
to another or movement in cellular location. They also
act as junctions between components and as such may
have multiple inputs or outputs to components. In the
mEPN all process nodes are represented by a small circu-
lar glyph and the process they represent is defined by a
one-to-three letter code. Colour is used as a visual clue
for quick recognition of the nature of the process
depicted and group processes into 'type' but again is not
necessary for inferring meaning. There are currently 31
process nodes recorded under the mEPN. Different pro-
cess nodes generally have different connections. For
instance a 'binding' node will have multiple inputs and
one output, the opposite is true for a dissociation node.
Process nodes also act as way of collating information
about a given event; for example protein A may be
cleaved by protein B, this reaction being ATP dependent.
In this case A would be shown connected to its truncated
form (A [t]) via a process node depicting cleavage (X). B
would be shown to catalyze or active that process
through its connection to the X-process node which
would also receive an input from an energy transfer node
(ATP->ADP) (See Additional file 3).
Boolean Logic Operators
Boolean logic operators define the dependencies between
components of a system describing the relationship
between multiple inputs into a process. An 'AND' opera-
tor is used when two or more components are required to
bring about a process i.e. an event is dependent on more
than one factor being present. In modelling flow through
networks these act in a similar manner to 'bind' process
nodes i.e. all inputs must be present before a product is
formed or reaction proceeds. In contrast an 'OR' operator
is used when one component or another may orchestrate
the same change in another component. For instance
multiple kinases e.g. MAP2K3, MAP2K6, MAP2K7 may
catalyze the phosphorylation of p38 (MAPK14) and
therefore shown connecting with p38 via an OR operator.
OR operators have also occasionally been used to infer
that a component(s) has potentially multiple out comes.
Other Nodes
There are a number of glyphs that represent concepts
that do not sit neatly under the headings of being a com-
ponent, a process or logic operator. These include:
Energy/molecular transfer nodes are used to represent
simple co-reactions associated with or required to drive
certain processes (e.g. ATP T ADP, GTP T GDP, NADPH
T NADP+). They are linked directly to the node repre-
senting the process in which they take part.
Conditional gates are used where there are potentially
multiple fates of a component and the output is depen-
dant on other factors such as the components concentra-
tion, time or is associated with a cellular state. These have
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point controls in cell cycle where the decision to go on to
the next phase cell replication is under the control of a
number of factors and two or more outcomes are possi-
ble. Another example is where cholesterol, depending on
its intracellular concentration, may be either exported out
of the cell or trigger the cholesterol synthesis pathway.
Pathway modules define complicated processes or
events that are not otherwise fully described. Examples
include signaling cascades, endocytosis, compartment
fusion etc. They are a short-hand way of representing
molecular events that are not known, not recorded or not
shown.
Pathway outputs detail the cumulative output of series
of interactions or function of an individual component at
the 'end' of a pathway. Pathway outputs are shown in
order to describe the significance of those interactions in
the context of a biological process or with respect to the
cell. The input lines leading into a pathway output node
have been coloured light blue to emphasize the end of the
pathway description.
Compartments
A cellular compartment can be a region of the cell, an
organelle or cellular structure, dedicated to particular
processes and/or hosting certain sub-sets of components
e.g. genes are found only in the nuclear compartment.
Sub-cellular compartments are defined by a labelled
background to the pathway and arranged with spatial ref-
erence to cell structure. Compartments are coloured dif-
ferently for emphasis and to ease awareness the location
of components. A proposed colour scheme for compart-
ments is shown in Figure 1. Similar or related compart-
ments share the same fill colour but have different
coloured perimeters to define internal boundaries within
a compartment e.g. membrane vs. lumen or to define the
origin of compartments e.g. different classes of vesicles
derived from the endoplasmic reticulum or plasma mem-
brane.
IFNγ Activation of MHC class II Gene Expression: A Worked 
Example of the mEPN in Use
In order to demonstrate the pathway notation system in
action on a scale that can be viewed in this format, we
have extracted a small section of our efforts in depicting
macrophage biology [17,18]. Figure 3 depicts the activa-
tion of MHC class II genes by interferon-gamma (IFNG)
as described in the literature and represented here using
the mEPN scheme. Going through these series of events
in detail:
IFNγ is secreted by T and NK cells upon activation [19-
21] (not shown). It oligomerises to form a homodimer
which then binds of to its receptor complex situated in
the plasma membrane of macrophages [22]. This com-
plex is formed from IFNGR1, IFNGR2, JAK1 and JAK2
[23,24], two copies of all proteins being present in the
receptor complex. Binding of IFNγ causes the autophos-
phorylation of JAK2 [25] which in turn phosphorylates
STAT1 [23]. The autophosphorylation of JAK2 can be
inhibited by SOCS1 or SOCS3 [26,27], and the activated
complex dephosphorylated by PTPN2 [28,29]. STAT1
now activated, oligomerises, is further phosphorylated by
PRKCD [30] and translocates to the nucleus where it
directly activates gene expression by binding to STAT
sites present in the promoters of numerous genes. Shown
on the diagram are just two of these genes, SOCS1 and
IRF1 [31,32]. These form feedback inhibition and feed-
forward activation loops, respectively. SOCS1 blocking
further signal propagation through the inhibition of the
IFNγ receptor complex (reviewed in [33] and IRF1 being
necessary for the activation of STAT1 expression as well
as being a necessary component of the CIITA transcrip-
tional initiation complex [34]. At least two complexes are
reported to be necessary to activate the expression of
CIITA (reviewed in [35], the first composed of STAT1,
IRF1, USF1 and IRF2 which binds to the so called pIV ele-
ment of the CIITA, the second is comprised of STAT1,
CREB1, RUNX2/3, TCF3, SPI1 and IRF4 which binds to
the pIII element of the gene. CIITA is a co-activator and
the key missing element in the transcription of MHC
class II genes. Once translated it binds to a preassembled
transcription factor complex, including members of the
RFX and NFY family of proteins and CREB1, thereby
activating the expression of the MHC class II genes [35].
This class of genes includes CD74, HLA-DPA/B, HLA-
DQA/B, HLA-DRA/B [33,36] and through combinatorial
assembly form a wide variety of complexes denoted here
generically as CD74 (li):HLA-D (alpha):HLA-D (beta). It
is this class of complexes that is shown in the main dia-
gram to go on through a long series of steps to bind pep-
tide antigen derived from the lysosomal degradation of
pathogen proteins and present them to T-helper cells. As
such this diagram serves as a graphical representation of
the known pathway connecting IFNγ secretion to the
activation of MHC class II antigen presentation.
Our work developing this notation scheme has reached
a point where we foresee little need to change the major-
ity of the mEPN scheme as presented here. Clearly the
modeling of other systems and ideas from others however
may in the future present a case for further modifications
or refinements.
Visualization of Pathway Information in 3D Environments
The reliance of the mEPN scheme on the principles of
network graphs and use of simple node shapes, labels,
edges and colour to convey pathway information has pre-
sented us with the opportunity to examine the use of
other environments in which to visualize pathways. Lay-
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scalability associated with visualizing very large pathway
diagrams and offers a little explored environment to visu-
alize and interact with pathway models. Here we present
for the first time a 3D translation of mEPN scheme (Fig-
ure 4). The scheme is devised to reflect the colours and
where possible glyphs used in the 2D mEPN process dia-
grams converting the 2D shapes into 3D objects. The pro-
posed notation mEPN3D scheme is currently supported
by the network visualization and analysis tool BioLayout
Express3D [37,38]http://www.biolayout.org/. This tool
now supports the direct import of pathways as .graphml
files, the main file type used by us to support our pathway
modeling efforts. The potential of representing pathways
in 3D environments is discussed below and elsewhere
[16,17].
Discussion
Pathway diagrams act as a visual representation of known
portions of the vast molecular network that underpins all
aspects of biological function. Models of pathways pro-
duced either as a graphical representation of known
events or as a resource for mathematical modelling, are
fundamental to understanding the workings of biological
systems. However the task of assimilating the large
amounts of available data and representing this informa-
tion in an intuitive manner remains a challenge. Accord-
ingly there has been increasing interest in the biology
community to develop approaches for representing bio-
logical pathways. The Molecular Interaction Map (MIM)
and Process Description Notation schemes were pro-
posed by Kurt Kohn [10,39] and Hiroaki Kitano (Kitano
2005), respectively, and their ideas laid the foundations
for much of the work on pathway notation that has fol-
lowed. The current mEPN scheme is the based on ideas
from the PDN and original EPN schemes but importantly
the experience of over four years of pathway construc-
tion, notation testing and discussions.
The objectives of the EPN as originally proposed
remain preserved, as do many of the original concepts of
the EPN and PDN schemes [9,11]. However substantial
modifications have been made to the notation system
from the introduction of new symbols to changes in the
aesthetics of the scheme and pathway syntax in order to
achieve our original objectives. Firstly, we wanted a nota-
tion system that was flexible enough to allow the detailed
representation of diverse biological entities, interactions
and pathway concepts. In this respect, we have used the
mEPN as described here not only in the construction of
the large macrophage pathway diagrams [16-18] which in
their own right cover a diverse range of signalling and
effector pathways, but also for the depiction of choles-
terol metabolism and the cell cycle (not shown). In all of
these endeavours the mEPN scheme has been able to
Figure 3 Graphical Representation of the Interferon-gamma Pathway Leading to MHC class 2 Antigen Presentation. Shown here are the 
known events between the release of IFNγ and the subsequent up-regulation of MHC class 2 antigen presentation by macrophages using the mEPN 
scheme. See results for a full description of this pathway.
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tems and where it was formerly unable to support a con-
cept, it was modified to allow us to do so. Secondly, we
wanted a system for presenting pathway knowledge in a
semantically and visually unambiguous manner. To some
degree this is down to actually labelling components in a
way that is unambiguous. The use of standard gene
nomenclature to label genes/protein components,
together with a formalized system to describe modifica-
tions to them, goes someway to achieving this. This has
meant in many cases that we have needed to first decon-
volute the literature which describes these systems using
numerous different names for the same protein or com-
plex. It means however that one component is unlikely
ever to be represented more than once but with different
names. It also facilitates use of the diagrams in the inter-
pretation of experimentally derived data which is fre-
quently annotated using standard gene nomenclature.
Our third aim, which is related to the second, is that dia-
grams are as simple as possible to construct and are
understandable by a biologist. To help ensure this to be
the case all the work in creating our pathway diagrams
has been performed by relatively junior biologists (MSc/
PhD students). They have been encouraged to discuss
their ideas and their pathways with each other so as iron
out areas where the information is not clearly depicted.
For this to happen they must be able to communicate
complicated biological concepts using the diagrams. The
readability of a diagram is not only dependent on the
notation system but also on its layout. Although a variety
of automated layout algorithms exist for network graphs
they do not perform as well as a human curator with an
artistic eye for the task. Pathway layout is relatively trivial
for small diagrams, but a long time has had to be spent on
optimizing the layout all of our large pathways so that
they are relatively easy to interpret. However, large inte-
grated pathway diagrams, like the systems they represent,
are inevitably complex. Finally, pathway diagrams are
central to efforts to computationally model the observed
behaviour of biological systems [40]. Our fourth objective
has therefore been to develop the mEPN such that the
semantics of the resulting network diagrams are suffi-
ciently well defined that software tools can convert
graphical models into formal models, suitable for analysis
Figure 4 mEPN3D Scheme. Presented here is a conversion of the standard mEPN scheme into a series of shapes that can be used to depict the same 
pathway concepts in 3D environments.
COMPONENT
PEPTIDES OR PROTEIN
GENE OR DNA SEQUENCE
GENERIC ENTITY
ION/ SIMPLE MOLECULE
SIMPLE BIOCHEMICAL
DRUG
PROCESS NODES
OTHER
BOOLEAN LOGIC 
OPERATORS
PROTEIN COMPLEX
BINDING
DISSOCIATION
TRANSLOCATION
TRANSCIPTION/ 
TRANSLATION
ACTIVATION
INHIBITION
CATALYSIS/ AUTO-CATALYSIS
RATE-LIMITING CATALYSIS
CLEAVAGE/ AUTO-CLEAVAGE
SECRETION
OTHER PROCESSES
AND
OR SINK/ PROTEASOMAL 
DEGRADATION
CATALYSIS
ACTIVATION
INHIBITION
PATHWAY OUTPUTPATHWAY MODULE
CONDITIONAL 
SWITCH
ENERGY/ 
MOLECULAR
TRANSFER
EDGE ANNOTATION
Glyph: Sphere Glyph: Cubes / Torus
Glyph: Cylinder
Glyph: Octahedral Diamond
Glyph: Dodecahedron/ Tetrahedron/ Icosahedron
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efforts has been to create a graphical model of events, we
have been mindful to construct pathway diagrams as
directional networks that could in principle support stud-
ies on the dynamics of these systems. In examining vari-
ous approaches to pathway modelling some are clearly
not scalable, such as those using ordinary differential
equations (ODEs) that require interaction parameters to
be known or computed. Other approaches do not sup-
port the modelling of the co-dependencies between com-
ponents of a pathway or give quantitative outputs
(reviewed in [36,41]. However the recently published sig-
naling Petri net (SPN) [42] potentially allows us to use
diagrams constructed using the mEPN scheme to study
the 'flow' of information through pathways. The SPN
algorithm uses stochastic flow simulations to distribute
'tokens' representing quantitative estimates of activity
through a network graph over time using only the net-
work structure to determine outcomes. The technique
has the advantage of offering fast computational simula-
tions on large networks (< 1 sec for ~100 node networks),
can support concepts of co-dependency between compo-
nents and requires no kinetic details for interactions. In
this way it should be possible to estimate the dynamics of
information flow through a network and the effects of
perturbations on that flow. Pathways drawn using the
mEPN system can easily be converted into a bipartite
graph of places (nodes) and transitions connected by arcs
(edges) that are required to support this approach. We are
currently exploring how SPN modelling might be used to
better understand the structure and activity of the signal-
ling systems of interest to us.
One advantage of the simple node and edge based
approach to pathway element depiction is that it facili-
tates mEPN's conversion into other software environ-
ments. Graphml files (the main file exchange format used
by the yEd editor) are supported by other network pro-
grams such as NodeXL http://www.codeplex.com/
NodeXL, Sonivis http://www.sonivis.org/, GUESS http://
guess.wikispot.org/GraphML, Pajek http://pajek.imfm.si/
doku.php and NetworkX http://networkx.lanl.gov/ and
the use of standard shaped nodes (glyphs) means that
other generic network analysis tools such as Cytoscape
[44] could also be used to draw mEPN diagrams. In par-
ticular we have been developing mEPN's compatibility
with BioLayout Express3D, a network analysis tool devel-
oped by us for the visualization and analysis networks
derived from 'omics data [37,38]. We have recently imple-
mented a parser that supports the import of .graphml
files into BioLayout Express3D. This translates the visual
characteristics and layout as defined by the original
.graphml 2D node co-ordinates of mEPN pathway dia-
grams from yEd in to a series of 3D objects, each repre-
senting a different class component using a combination
of shape, size and colour (Figure 4). Translating a 2D
pathway into a 3D environment arguably offers no advan-
tage for small diagrams. Indeed in 3D, arrowheads and
polylines are not currently supported. However, when
diagrams become large, pathways be rotated and viewed
from any angle, zoomed in on and generally manipulated
in an environment which is quite different to that of any
2D representation. In the 3D environment colour is a
powerful device that can be used to further overlay visual
information on to nodes (Figures 5a, b). Indeed we have
now built in the ability of BioLayout Express3D to directly
export the analyses of one graph e.g. clusters from
expression data and import and overlay this information
on to another, in this instance a pathway (Figure 5c). It is
also possible to imagine much larger models of pathway
systems where the spatial layout of components in 3D
space is based on a components cellular location (Figure
5d). With BioLayout Express3D now capable of supporting
networks comprising of up to 30,000-40,000 node graphs
there is considerable scope for building ever larger path-
way models and further exploring the potential of 3D
environments for pathway visualization and analysis. One
final use of the 3D environment is as a means to visualize
pathway activity. We are now working on a version of
BioLayout Express3D that will harness the power of the
Figure 5 Pathway Representation in 3D Environment. Large mac-
rophage activation pathway rendered in 3D environment where node 
shape, size and colour represents a components identity. (A) Nodes 
coloured according to type e.g. light blue - proteins, yellow - protein 
complexes, purple - generic molecular species. All process nodes are 
depicted as small cubes and coloured according to type. (B) Nodes 
coloured according to cellular location e.g. brown - plasma mem-
brane, yellow - cytoplasm, purple - endosome, green nucleus. Process 
nodes/Boolean logic operators are shown as having no cellular loca-
tion and are coloured dark blue (no class). (C) Nodes coloured accord-
ing to overlay of data, in this case expression data. Colour of nodes 
represents co-expression cluster following stimulation of mouse mac-
rophages with Ifnβ (D) A representation of the interferon-beta signal-
ling pathway and the transcriptional network it controls. The signalling 
network is represented using the mEPN3D notation with the addition of 
transition nodes for use in modelling studies. Connected to it are clus-
ters of genes up or down regulated by Ifnb which have been stacked 
in at different layers depending on the their time course of activation/
repression.
A B
C D
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Page 10 of 13OpenGL 3D graphics to animate analyses of flow through
a pathway, again using a node's shape, size and colour to
indicate a components activity during dynamic simula-
tions of pathway activity.
Running concurrently with our work has been an ongo-
ing community effort to establish rules for best practice
in pathway depiction. The Systems Biology Graphical
Notation http://www.sbgn.org/ project has been discuss-
ing issues and ideas around this topic and a manuscript
describing the SBGN Process Diagrams Level 1 specifica-
tion was recently published [43]. The mEPN scheme as
described here aspires to many of the same goals as the
SBGN and where possible we have tried to harmonize the
mEPN scheme to the emerging SBGN specification.
However, our biologist centric approach to this problem,
combined with a lack of flexible pathway editing tools,
the scale our diagrams and the range of biological systems
we have attempted to map, have all played their part in
determining the design and implementation of the mEPN
scheme. As a result there are a number of important dif-
ferences that exist between the mEPN as described here
and the SBGN scheme for process description language
as currently proposed (level 1, version 1.1). Firstly, in
common with the proposed SBGN scheme, the mEPN
uses glyphs of a specific shape to define the class of a
component although there are some differences between
the two schemes (Figure 6a). However, under the SBGN
scheme the glyph representing a multimeric protein com-
plex is comprised of each protein in a complex being
depicted separately, modifications to them being overlaid
on top of these and the whole thing is enclosed by a con-
tainer node. We have found this a considerable overhead
to implement and can interfere the clarity of what is
depicted rather than enhancing it (Figure 5b). Further-
more the notation scheme is not supported by many of
the general purpose network visualization tools e.g. yEd,
Cytoscape, Biolayout Express3D [44-46] in general use,
requiring instead the use of dedicated pathway software.
Given the relatively recent publication of the SBGN spec-
ification tools to support its deployment are largely still
under development. As a result the mEPN scheme gener-
ally uses a single standard shape to depict a component
even when made up of more than one entity or a series of
attached entities (Figure 2d &2e). It relies on a labelling
system to define the exact identity and make up of the
component and its state e.g. the protein subunits that
make up protein complex and their modifications (Figure
6b). Secondly, we have avoided the use of different arrow-
heads to depict the nature of interactions (edges). The
meaning of numerous arrowheads can be challenging to
remember and again they are not always supported by
general pathway/network editing software packages.
Instead mEPN uses inline annotation nodes to depict the
meaning of edges which carry a letter symbolizing the
meaning of the edge e.g. A for activation, I for inhibition,
and may also use colour as an additional visual clue (Fig-
ure 6c). In principle this approach could support a wide
range of edge meanings but in practice we have found
many of the edge concepts supported by SBGN of no use
in our mapping efforts and hence have not been included
in the mEPN scheme. For instance a consumption arc
(edge) as defined by SBGN is 'used to represent the fact
that an entity affects a process, but is not affected by the
process' and a production arc is 'used to represent the fact
that an entity is produced by a process.' In the first
instance, then this is the case with many enzymes acting
on their substrate and in the second instance it is obvious
by the fact that one thing leads on to another. In both
cases we see this information as self-evident with no need
for specific notation to depict it. In the case of the inclu-
sion of specific edges to define a 'modulation' then the
question is what kind of modulation is this and how
would one interpret or model such a vague concept and
the mEPN equivalent of the 'stimulation' edge is an acti-
vation edge. Finally, mEPN uses labelled process nodes to
explicitly state the nature of interactions between compo-
nents. In the proposed SBGN scheme process nodes are
used, but generally not as a means to convey the nature of
interactions except in the case of protein binding (associ-
ation) and dissociation (Figure 6d). Whilst this approach
is understandable on the basis that most process nodes
would function similarly during computational modelling
of such systems, not depicting the nature of the process
whereby one component is transformed to another does
impair visual interpretation of the diagrams. Therefore
the mEPN provides a visual clue as to the nature of inter-
action using a one-to-three letter key to represent the
nature of the process being depicted. When pathways are
large and the distance between interacting species may be
great, this can be an important visual aid to reading the
diagrams. There are a number of other differences
between the two schemes and full description of the dif-
ferences between the SBGN level 1 notation and the
mEPN described here can be found in Additional file 4.
Whilst on these and other points the mEPN and SBGN
schemes may differ, we are fully supportive of the princi-
ple of promoting the adoption of a common notation sys-
tem for pathway depiction and hope that current the
work will contribute to this end.
There are significant efforts already underway to garner
the support and interest of the wider biological commu-
nity in assembling resources, information and pathway
diagrams covering a broad spectrum of biology. Indeed,
the need has never been greater for these resources.
However, if they do not record pathways in a standard-
ized way, integration of the results of these efforts will
continue to be a considerable issue. To this end we are
fully supportive of the SGBN's effort to promote the prin-
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Page 11 of 13ciples of standard notation systems even if we can not
fully support the proposed SBGN specification for pro-
cess diagrams. We present this work and accompanying
website http://www.mepn-pathway.org/ in the hope that
it is as positive contribution to the debate about how best
to graphically model pathway knowledge.
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